Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study

S. Ladjevardi, A. Ebner, A. Femic, NA. Huebner, SF. Shariat, S. Kraler, RA. Kubik-Huch, RC. Ahlman, M. Häggman, LJ. Hefermehl

. 2024 ; 54 (6) : e14192. [pub] 20240306

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24013765

BACKGROUND: High-intensity focused ultrasound (HIFU) emerged as a novel approach for the treatment of localized prostate cancer (PCa). However, prospective studies on HIFU-related outcomes and predictors of treatment failure (TF) remain scarce. MATERIALS AND METHODS: We conducted a multinational prospective cohort study among patients undergoing HIFU therapy for localized, low- to intermediate-risk PCa. Follow-up data on serial prostate specific antigen (PSA), multi-parametric magnetic resonance imaging (mpMRI), targeted/systematic biopsies, adverse events and functional outcomes were collected. The primary endpoint was TF, defined as histologically confirmed PCa requiring whole-gland salvage treatment. Uni- and multi-variable adjusted hazard ratios (HRs) were calculated using Cox proportional hazard regression models. RESULTS: At baseline, mean (standard deviation) age was 64.14 (7.19) years, with the majority of patients showing T-stage 1 (73.9%) and International Society of Urological Pathology grading system Grade 2 (58.8%). PSA nadir (median, 1.70 ng/mL) was reached after 6 months. Of all patients recruited, 16% had clinically significant PCa, as confirmed by biopsy, of which 13.4% had TF. Notably, T-stage and number of positive cores at initial biopsy were independent predictors of TF during follow-up (HR [95% CI] 1.27 [1.02-1.59] and 5.02 [1.80-14.03], respectively). Adverse events were minimal (17% and 8% early and late adverse events, respectively), with stable or improved functional outcomes in the majority of patients. CONCLUSIONS: This interim analysis of a multinational study on HIFU therapy for the management of low-to-intermediate-risk PCa reveals good functional outcomes, minimal adverse events and low incidence of TF over the short-term. Data on long-term outcomes, specifically as it relates to oncological outcomes, are awaited eagerly.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013765
003      
CZ-PrNML
005      
20240905134010.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/eci.14192 $2 doi
035    __
$a (PubMed)38445798
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ladjevardi, Sam $u Department of Urology, University of Uppsala, Uppsala, Sweden
245    10
$a Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study / $c S. Ladjevardi, A. Ebner, A. Femic, NA. Huebner, SF. Shariat, S. Kraler, RA. Kubik-Huch, RC. Ahlman, M. Häggman, LJ. Hefermehl
520    9_
$a BACKGROUND: High-intensity focused ultrasound (HIFU) emerged as a novel approach for the treatment of localized prostate cancer (PCa). However, prospective studies on HIFU-related outcomes and predictors of treatment failure (TF) remain scarce. MATERIALS AND METHODS: We conducted a multinational prospective cohort study among patients undergoing HIFU therapy for localized, low- to intermediate-risk PCa. Follow-up data on serial prostate specific antigen (PSA), multi-parametric magnetic resonance imaging (mpMRI), targeted/systematic biopsies, adverse events and functional outcomes were collected. The primary endpoint was TF, defined as histologically confirmed PCa requiring whole-gland salvage treatment. Uni- and multi-variable adjusted hazard ratios (HRs) were calculated using Cox proportional hazard regression models. RESULTS: At baseline, mean (standard deviation) age was 64.14 (7.19) years, with the majority of patients showing T-stage 1 (73.9%) and International Society of Urological Pathology grading system Grade 2 (58.8%). PSA nadir (median, 1.70 ng/mL) was reached after 6 months. Of all patients recruited, 16% had clinically significant PCa, as confirmed by biopsy, of which 13.4% had TF. Notably, T-stage and number of positive cores at initial biopsy were independent predictors of TF during follow-up (HR [95% CI] 1.27 [1.02-1.59] and 5.02 [1.80-14.03], respectively). Adverse events were minimal (17% and 8% early and late adverse events, respectively), with stable or improved functional outcomes in the majority of patients. CONCLUSIONS: This interim analysis of a multinational study on HIFU therapy for the management of low-to-intermediate-risk PCa reveals good functional outcomes, minimal adverse events and low incidence of TF over the short-term. Data on long-term outcomes, specifically as it relates to oncological outcomes, are awaited eagerly.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x terapie $x patologie $7 D011471
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a prostatický specifický antigen $x metabolismus $x krev $7 D017430
650    _2
$a prospektivní studie $7 D011446
650    _2
$a transrektální ultrazvuk o vysoké intenzitě $7 D036761
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a záchranná terapie $x metody $7 D016879
650    _2
$a ablace intenzivním ultrazvukovým paprskem $x metody $7 D057086
650    _2
$a multiparametrická magnetická rezonance $7 D000081364
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a kohortové studie $7 D015331
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Ebner, Anna $u Department of Urology, Cantonal Hospital Baden, Baden, Switzerland $u Department of Urology, University Hospital Zurich, Zurich, Switzerland $1 https://orcid.org/0009000193205931
700    1_
$a Femic, Aleksandar $u Department of Urology, University of Uppsala, Uppsala, Sweden
700    1_
$a Huebner, Nicolai A $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria $u Department of urology, University of California Davis, Sacramento, California, USA
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Division of Urology, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
700    1_
$a Kraler, Simon $u Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland $u Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland $1 https://orcid.org/0000000282457287
700    1_
$a Kubik-Huch, Rahel A $u Department of Radiology, Cantonal Hospital Baden, Baden, Switzerland $1 https://orcid.org/0000000236368697 $7 ntk20221159596
700    1_
$a Ahlman, Rafaele C $u Department of Urology, University of Uppsala, Uppsala, Sweden
700    1_
$a Häggman, Michael $u Department of Urology, University of Uppsala, Uppsala, Sweden
700    1_
$a Hefermehl, Lukas J $u Department of Urology, Cantonal Hospital Baden, Baden, Switzerland
773    0_
$w MED00009632 $t European journal of clinical investigation $x 1365-2362 $g Roč. 54, č. 6 (2024), s. e14192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38445798 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134004 $b ABA008
999    __
$a ok $b bmc $g 2143523 $s 1225631
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 54 $c 6 $d e14192 $e 20240306 $i 1365-2362 $m European journal of clinical investigation $n Eur J Clin Invest $x MED00009632
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options